All

Results: 853-864 of 48203

PR Newswire associated0

NYSE Content advisory: Pre-Market update + Trump announces new tariffs on 14 countries

Business Wire associated0

Kobo Resources Launches Limited Edition Jersey to Support Village Communities Through Kobo Cup CSR Initiative

Champions Oncology Launches Radiopharmaceutical Services Platform, Expands Isotope License, and Screens More Than 30 PDX Models

Allegion Expands Access Solutions Portfolio with Innovative Waitwhile Software Platform

North Highland Welcomes Stephen Ardill as Senior Managing Director and EMEA Regional Lead

North Highland Welcomes Stephen Ardill as Senior Managing Director and EMEA Regional Lead

PR Newswire associated0

Elegoo Launches Exclusive Deals on Bestselling 3D Printers for Prime Day 2025

Boyd's high capacity ROL2300 in row coolant distribution unit (CDU) efficiently and reliably cools modern high power AI processors in hyperscale, colocation, and enterprise data centers with up to a 2.3 megawatt capacity. A single ROL2300 can efficiently cool over 10 NVL72 racks. It is optimized to easily fit in data center server rows and designed to maximize service and maintenance efficiency. With high-capacity flow and pressure capabilities, customers are enabled to use fewer CDUs in AI liquid cooling applications.

Boyd Unveils a High-Capacity Coolant Distribution Unit with a 2.3 Megawatt Capacity for AI Liquid Cooling Applications

Q’s dashboard gives investor relations professionals instant insights into ownership trends, peer activity, and shareholder engagement, all in one place.

Q4 Revolutionizes Investor Relations with the Launch of Q, the First IRO Agent™

Esri Launches New E-Commerce Experience for Demographic Data

Heng Qin® is the first and only drug approved to treat DED associated with MGD and will be available to patients in China in the coming months.

Breakthrough in Ophthalmology! Hengrui’s Heng Qin® (Perfluorohexyloctane Eye Drops) Approved as First Treatment for Dry Eye Disease Associated with MGD

Vanderbilt Selects Parse Biosciences GigaLab to Generate Atlas of Early Neutralizing Antibodies to Measles, Mumps, and Rubella

Beacon Therapeutics completes enrollment in registrational Phase 2/3 VISTA trial of laru-zova for patients with XLRP